A new U.S. Senate spending proposal would extend federal protections for medical marijuana programs in 48 states, Washington, D.C., and four U.S. territories while allowing the federal government’s broader cannabis rescheduling process to continue. Released by the Senate Appropriations Committee on November 12, 2026, the legislation would prevent the Department of Justice from using federal funds to interfere with qualifying state medical cannabis laws through September 2027. The proposal maintains a longstanding congressional safeguard that has protected state-regulated medical marijuana programs from certain federal enforcement actions for more than a decade.
The legislation also establishes a significant difference between the Senate and House approaches to federal cannabis policy. Earlier this year, House appropriators advanced a spending bill containing language that would prohibit federal funds from being used to reschedule or deschedule marijuana under the Controlled Substances Act. The Senate version contains no such restriction, preserving the possibility that federal officials could continue moving cannabis toward less restrictive classification. The disagreement comes as the Drug Enforcement Administration evaluates broader marijuana rescheduling and federal regulators implement new rules governing qualifying medical cannabis businesses.
Senate Appropriations Committee Proposes Extending Medical Marijuana Protections
The medical marijuana provision appears in Section 531 of the Senate’s fiscal year 2027 Commerce, Justice, Science, and Related Agencies Appropriations Act. The 141-page proposal was released alongside four additional federal spending measures addressing government operations, national security, scientific research, and other priorities. Section 531 would prohibit the Justice Department from using money provided under the legislation to prevent covered states and territories from implementing laws authorizing medical marijuana cultivation, distribution, possession, or use. The restriction applies to federal enforcement spending rather than changing how individual states regulate cannabis.
The proposal would continue protections first established in December 2014 through the Rohrabacher-Farr Amendment, a congressional spending provision that has been renewed through successive appropriations bills. Although the safeguard has become a familiar part of federal cannabis policy, it must be maintained through annual funding legislation or temporary spending extensions. The Senate’s latest draft would preserve that approach during the federal fiscal year ending September 30, 2027. However, the legislation remains a committee proposal rather than enacted law, and Senate appropriators had not scheduled a vote on the measure as of November 14.
Medical Marijuana Programs in 48 States Would Remain Protected
The proposed language identifies 48 states, the District of Columbia, Puerto Rico, Guam, the U.S. Virgin Islands, and the Commonwealth of the Northern Mariana Islands. Idaho and Kansas are the only two states excluded from the list. This broad geographic coverage reflects the expansion of state cannabis policies since the original congressional protection was adopted. However, inclusion does not mean that every state has established a comprehensive medical marijuana dispensary program. Some jurisdictions maintain comparatively restrictive systems allowing only particular cannabis formulations, limited THC concentrations, or access for patients with narrowly defined qualifying conditions.
The distinction matters because Section 531 protects the implementation of medical marijuana laws actually authorized by each jurisdiction. It does not independently create patient rights in states without broad medical cannabis programs, nor does it require governments to establish dispensaries or expand qualifying conditions. States remain responsible for determining which patients may obtain medical marijuana, which businesses can operate, and what products are permitted. The federal spending restriction instead limits the Justice Department’s ability to interfere with activities authorized under those state laws, preserving an important boundary between federal enforcement authority and state medical cannabis regulation.
Federal Medical Marijuana Protections Have Existed Since 2014
The current proposal builds on a federal policy that emerged during the early expansion of state medical marijuana programs. In December 2014, Congress approved an appropriations amendment sponsored by Representatives Dana Rohrabacher of California and Sam Farr of California. The amendment prevented the Justice Department from spending appropriated funds to interfere with states implementing their medical cannabis laws. At the time, marijuana remained federally classified as a Schedule I controlled substance, and state-licensed businesses operated under considerable uncertainty about the possibility of federal prosecution.
The provision became especially important following a 2016 federal appeals court decision in United States v. McIntosh. The U.S. Court of Appeals for the Ninth Circuit concluded that the spending restriction could prevent federal prosecutors from pursuing cases involving individuals whose medical marijuana activities were fully authorized by applicable state law. However, the court emphasized that participants must strictly comply with state requirements to benefit from the protection. The ruling also recognized that the restriction was temporary because Congress could decline to renew it. Consequently, the amendment established a meaningful limitation on federal prosecution without permanently legalizing marijuana or eliminating the underlying controlled-substance restrictions.
What the Senate’s Medical Marijuana Protection Actually Covers
The proposed restriction would primarily protect the operation of state medical marijuana systems from interference financed through the Justice Department’s appropriations. This can include federal enforcement activity intended to prevent states from carrying out laws authorizing medical cannabis cultivation, distribution, possession, and use. Because the DEA operates within the Justice Department, the spending restriction also has implications for federal drug enforcement involving state-authorized medical marijuana. However, its application depends on the circumstances of a particular case and whether the conduct is genuinely permitted under applicable state law.
The legislation does not provide unrestricted legal immunity to every medical marijuana patient, dispensary, or cannabis business. Activities exceeding possession limits, unauthorized commercial distribution, unlicensed cultivation, and other violations may remain subject to prosecution. The restriction also does not automatically bind every federal agency, invalidate unrelated federal statutes, or establish nationwide cannabis legalization. For businesses, strict adherence to state licensing requirements, product rules, inventory controls, and permitted distribution activities remains essential. The distinction between restricting federal enforcement spending and formally removing cannabis prohibitions is central to understanding the proposal’s practical significance.
Senate Rejects House Effort to Block Federal Marijuana Rescheduling
One of the most consequential aspects of the Senate proposal is the absence of a provision included in the House Appropriations Committee’s fiscal year 2027 spending bill. House Bill 8845 contains Section 591, which would prohibit the use of designated federal funds to reschedule marijuana or remove it from the Controlled Substances Act entirely. If enacted, that language could interfere with the federal government’s ongoing administrative process to move cannabis into a less restrictive category. It could also restrict efforts to remove marijuana from federal scheduling through administrative action, depending on the final legislation’s scope.
The Senate’s decision not to include an equivalent restriction creates an important negotiating difference between the chambers. The Senate proposal does not itself order the DEA to reschedule marijuana, establish a deadline, or determine the outcome of the administrative proceeding. Instead, it avoids creating a new appropriations barrier to that work. Congressional negotiators will eventually need to determine whether the House provision survives, is modified, or disappears from the final spending agreement. The outcome could influence the speed and direction of federal cannabis reform, particularly as regulators evaluate the scientific, medical, and legal considerations surrounding broader Schedule III classification.
Federal Schedule III Marijuana Rescheduling Continues Separately
The debate follows the Justice Department’s April 2026 decision to move FDA-approved marijuana-containing medications and cannabis products regulated under qualifying state medical marijuana licenses into Schedule III. That decision recognized certain medical cannabis activities within a less restrictive federal classification while maintaining controlled-substance requirements. It also established a pathway for eligible medical cannabis businesses to obtain federal DEA registration. Hundreds of state-licensed dispensaries have since received registrations, creating a new relationship between state medical cannabis industries and federal drug regulators.
Broader marijuana rescheduling remains a separate question. The DEA conducted formal hearings between June 29 and July 15, 2026, to evaluate whether marijuana outside the limited medical framework should also move from Schedule I to Schedule III. A final decision had not been issued as of November 14. Rescheduling could affect research requirements, federal business regulations, and tax treatment, including the application of Section 280E to qualifying activities. However, Schedule III classification would not automatically authorize nationwide recreational marijuana sales or eliminate federal restrictions on unauthorized distribution. The Senate spending proposal would leave that broader administrative process free of the specific funding prohibition proposed by House appropriators.
Senate and House Differ Over Drug-Free School Zone Enforcement
Another difference between the two congressional proposals concerns federal penalties for distributing controlled substances near schools and other protected locations. The House version includes language clarifying that medical marijuana spending protections would not prevent enforcement of federal drug-free school zone laws. Under Section 860 of Title 21 of the United States Code, certain controlled-substance offenses committed within specified distances of schools, colleges, playgrounds, and public housing facilities can carry enhanced penalties. House lawmakers sought to make clear that the medical cannabis amendment should not interfere with those federal enforcement provisions.
The Senate draft does not include the House’s additional statutory exception. Instead, its accompanying explanatory statement acknowledges the Justice Department’s position that Section 531 does not explicitly prevent federal prosecutors from enforcing Section 860. Senate appropriators also encouraged continued efforts to keep schools and playgrounds free from illegal drug activity. This approach preserves the existing medical marijuana protection while addressing school-zone concerns through committee guidance rather than a new restriction written directly into the spending bill. The difference illustrates how lawmakers can agree on maintaining state medical cannabis protections while disagreeing over the precise boundaries of federal enforcement authority.
Senate Proposal Also Addresses Hemp Research and Illegal Cultivation
The legislation includes another cannabis-related spending protection in Section 530, which would prohibit the Justice Department and DEA from using federal funds in violation of specified provisions governing industrial hemp research under the Agricultural Act of 2014. This language continues an existing congressional restriction associated with state-authorized hemp research programs. Although the broader hemp industry operates under a substantially different federal framework following the 2018 Farm Bill and subsequent amendments, the provision demonstrates Congress’s continued attention to maintaining boundaries around federal enforcement of authorized agricultural research.
The Senate committee’s explanatory statement also addresses illegal marijuana cultivation operations potentially connected to foreign criminal organizations. It directs the Justice Department to prepare a report within 90 days of enactment evaluating illegal growing operations associated with foreign nationals, including possible connections to Chinese transnational criminal organizations or the Chinese government. The assessment would involve coordination among the FBI, DEA, and federal prosecutors. By preserving medical marijuana protections while seeking additional information about unlawful cultivation, the committee distinguishes state-authorized cannabis activity from operations suspected of violating criminal laws.
Congress Demands Answers About Federal Cannabis Seizures
A separate Senate Homeland Security spending proposal released November 12 addresses another dispute involving federal enforcement against state-legal marijuana businesses. Its accompanying report directs U.S. Customs and Border Protection to brief Congress within 120 days of enactment about seizures involving cannabis products or related paraphernalia possessed, sold, or transferred by businesses complying with applicable state or tribal regulations. The provision follows controversy surrounding federal seizures involving marijuana transported within states that have established legal cannabis markets.
New Mexico has been particularly affected by disputes involving federal border enforcement operations and state-authorized cannabis transportation. Governor Michelle Lujan Grisham previously criticized seizures targeting products moving within the state’s regulated marijuana system, arguing that federal enforcement actions created unnecessary disruptions for legitimate businesses. The Senate’s request does not prohibit Customs and Border Protection from conducting future seizures or establish new transportation rights. Instead, it seeks greater transparency about when and why federal agents confiscate cannabis associated with businesses operating under state or tribal law. The inquiry reflects the continuing complications created by overlapping federal and state cannabis authority.
Medical Marijuana Businesses Still Face Financial and Regulatory Uncertainty
For patients and licensed businesses, maintaining federal spending protections provides an additional measure of stability during a period of significant regulatory change. Medical marijuana companies have invested in cultivation facilities, dispensaries, product testing, employee training, and compliance systems under state licensing programs. Their ability to operate depends on predictable enforcement conditions and confidence that authorized medical cannabis activities will not suddenly become targets of federal intervention. Patients similarly depend on functioning state programs to obtain products they use under applicable medical marijuana laws.
Nevertheless, the appropriations rider does not eliminate the industry’s broader financial and operational challenges. Cannabis businesses may still encounter banking restrictions, difficulties obtaining affordable financing, complicated federal tax treatment, and uncertainty involving interstate commerce. The recent federal registration framework introduces additional compliance standards for qualifying medical operations, while businesses participating in both medical and recreational markets face distinct legal obligations. Preserving the spending restriction therefore serves as one component of federal cannabis policy rather than a comprehensive solution. Greater long-term certainty would require lawmakers and regulators to resolve the underlying conflicts between federal controlled-substance rules and state-authorized marijuana commerce.
December 11 Funding Deadline Creates Urgency for Congress
The next major development will involve negotiations over federal government funding. Existing medical marijuana protections remain in place under a temporary spending measure signed in September 2026, which is scheduled to expire December 11. Congress must either approve new appropriations legislation or adopt another temporary extension to avoid a funding lapse. The deadline gives lawmakers limited time to reconcile competing priorities, including the House proposal restricting marijuana rescheduling and the Senate’s decision to omit that language. Cannabis provisions represent only a small portion of the much larger federal spending negotiations, but their potential effects make them significant for patients, researchers, and businesses.
As of November 14, the Senate Appropriations Committee had released its draft but had not scheduled a vote. Neither the Senate proposal nor the House committee’s competing language had become the final fiscal year 2027 funding law. Lawmakers could retain the existing medical marijuana rider, alter its conditions, remove the House rescheduling restriction, or negotiate another arrangement as part of a broader spending package. If an agreement cannot be reached before the deadline, another temporary extension could maintain existing policies while delaying a final decision. The legislative outcome will determine whether the federal protections continue unchanged and whether the rescheduling process encounters new congressional funding restrictions.
What the Senate Proposal Means for the Future of Federal Marijuana Policy
The Senate’s fiscal year 2027 spending proposal represents a significant statement about the direction of federal cannabis regulation. By preserving protections covering 48 states, Washington, D.C., and four territories, the committee supports continuity for medical marijuana programs that have developed under state law. At the same time, its decision to omit the House’s anti-rescheduling provision leaves federal officials with room to continue evaluating broader changes to marijuana’s controlled-substance classification. The combination suggests an approach that distinguishes enforcement against unauthorized cannabis activity from the continued operation of legitimate state medical programs and the scientific review of federal drug policy.
The proposal does not legalize marijuana nationwide, guarantee the outcome of Schedule III rescheduling, or permanently protect every state cannabis business from federal prosecution. Its importance lies in maintaining a safeguard that has helped state medical marijuana programs operate for more than a decade while avoiding an additional obstacle to potential federal reform. As Congress approaches its December funding deadline, the final treatment of these provisions will provide an indication of whether lawmakers intend to preserve the existing balance between state medical cannabis access and federal oversight or introduce new restrictions on the government’s evolving marijuana policies.
